OnKure shareholders elect Manke and Saccomano as Class I directors, ratify KPMG as auditor for FY2025

OnKure Therapeutics, Inc.

Dr. Isaac Manke elected with 4,589,481 for, 882,303 withheld; Dr. Nicholas Saccomano with 5,209,380 for, 262,404 withheld.
KPMG LLP ratified as independent auditor for fiscal year ending December 31, 2025 (6,750,408 for, 111,715 against, 208 abstain).
Both directors will serve until the 2028 annual meeting of stockholders.
Broker non-votes totaled 1,390,547 for each director proposal.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.